Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 3,452 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Colorectal Cancer Clear all

Conditions: Advanced or Metastatic Colorectal Cancer
Interventions: Amivantamab IV, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan, Amivantamab; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 9 more

Conditions: Colorectal Cancer
Interventions: ISIS 2503; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Melanoma, Breast Cancer, Head and Neck Squamous Cell Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma
Interventions: Vaccinia virus (vvDD-CDSR); Biological
Lead sponsor: David Bartlett; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Liver Cancer, Anxiety Disorder, Depression, Small Cell Lung Cancer, Extrahepatic Bile Duct Cancer, Malignant Mesothelioma, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Non-small Cell Lung Cancer
Interventions: Early palliative care; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 23
States / cities: La Jolla, California • Honolulu, Hawaii • Chicago, Illinois + 20 more

Conditions: Colorectal Cancer, Lung Cancer, Breast Cancer
Interventions: Decision Making Support Tool; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 50 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Colon Adenocarcinoma, Colorectal Cancer
Interventions: TAS-102, Irinotecan, Standard Treatment, Signatera MRD ctDNA Assay; Drug · Combination Product · Diagnostic Test
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Orange, California

Conditions: Colorectal Cancer Screening
Interventions: Best clinical practices plus culturally targeted print materials, Best clinical practices plus standard print materials, Best clinical practices alone; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 50 Years to 85 Years
Enrollment: 386 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Polyp, Colorectal Adenoma, Colon Cancer
Interventions: Endocuff Vision; Device
Lead sponsor: Indiana University; Other
Eligibility: 40 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Colorectal Neoplasms
Interventions: Placebo, Metformin; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Little Rock, Arkansas

Conditions: Solid Tumors
Interventions: triacetyluridine, fluorouracil, leucovorin, camptosar; Drug
Lead sponsor: Wellstat Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Capecitabine, Computed Tomography, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other + 1 more
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 659
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 438 more

Conditions: Anxiety Disorder, Worry, Uncertainty, Sleep Disorders, Insomnia, Fatigue, Pain, Depression, Cognitive-behavioral Therapy, Psychological Intervention, Esophageal Cancer, Pancreatic Cancer, Leukemia, Lung Cancer, Multiple Myeloma, Ovarian Neoplasm, Stage III or IV Cervical or Uterine Cancer, Stage IIIB, IIIC, or IV Breast Cancer, Glioblastoma Multiforme, Relapsed Lymphoma, Stage III or IV Colorectal Cancer, Stage IIIC or IV Melanoma
Interventions: Cognitive-behavioral therapy for worry, uncertainty & insomnia; Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Metastatic Colorectal Cancer
Interventions: Inavolisib, Bevacizumab, Cetuximab, Atezolizumab, Tiragolumab, SY-5609, Divarasib, FOLFOX, FOLFIRI, FoundationOne®Liquid CDx; Drug · Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more

Conditions: B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer, Lymphoma, Melanoma, Ovarian Cancer, Glioblastoma
Interventions: Nivolumab, Epacadostat, Chemotherapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 16 more

Conditions: Colorectal Cancer
Interventions: Colonoscopy, Fecal immunochemical test (FIT); Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 75 Years
Enrollment: 50,126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 45
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 42 more

Conditions: Peritoneal Neoplasms
Interventions: nanoparticulate paclitaxel; Drug
Lead sponsor: CritiTech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Kansas City, Kansas • Wichita, Kansas • Oklahoma City, Oklahoma

Conditions: Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage III Colon Cancer AJCC v7, Stage III Rectal Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Colon Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
Interventions: Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pertuzumab, Trastuzumab, HER-2 testing; Biological · Drug · Other + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 786
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 501 more

Conditions: Rectal Cancer
Interventions: Etrumadenant (AB928), Radiation therapy, FOLFOX regimen, Zimberelimab (AB122); Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 3
States / cities: New York, New York

Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Lymphoma, Prostate Carcinoma
Interventions: Survivorship Care Plan, Educational Intervention, Questionnaire Administration, Supportive Care; Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Colorectal Cancer
Interventions: Capecitabine (Xeloda); Drug
Lead sponsor: James A. Haley Veterans Administration Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Colorectal Cancer
Interventions: Colonoscopic examination; Other
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 35 Years to 49 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Pertuzumab, Radiologic Examination, Trastuzumab; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer, Ovarian Cancer
Interventions: CDX1307; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 3
States / cities: Detroit, Michigan • Durham, North Carolina • Huntersville, North Carolina

Search by objective public record fields.

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer

Safety Study of Modified Vaccinia Virus to Cancer

Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers

Technology-Based Cancer Screening Intervention

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Improving Colorectal Cancer Screening for Diverse Hispanics in Urban Primary Care

Standard Colonoscopy Versus Colonoscopy With Endocuff Vision

Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth

Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study

Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma

Colorectal Cancer Screening for Cancer Survivors

Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)